Semaglutide's Expanding Reach: From Diabetes to Brain, Heart, and Liver

Semaglutide has rapidly evolved from a diabetes medication into one of the most versatile therapeutic agents in modern medicine. As a glucagon-like peptide-1 receptor agonist (GLP-1RA), it mimics the action of endogenous GLP-1, stimulating insulin secretion, suppressing glucagon, slowing gastric emptying, and acting on central appetite-regulating pathways. This broad mechanism underlies its effectiveness across a wide spectrum of metabolic and systemic diseases.

The SUSTAIN (subcutaneous) and PIONEER (oral) clinical trial programs established semaglutide's superiority in glycemic control, demonstrating clinically meaningful reductions in HbA1c and body weight compared to placebo and active comparators. Critically, SUSTAIN-6 showed a significant reduction in major adverse cardiovascular events (MACE), including nonfatal myocardial infarction and stroke, positioning semaglutide as a cardioprotective agent for high-risk diabetic patients. The STEP trial series extended these findings into the obesity space, with participants without diabetes achieving up to 20% body weight reduction alongside improvements in blood pressure, lipids, and quality of life.

Beyond glycemic and weight outcomes, the review highlights semaglutide's renoprotective effects, supported by reductions in albuminuria and slower progression of chronic kidney disease in trial subanalyses. The FLOW trial specifically evaluated renal outcomes, further strengthening this evidence base. Anti-inflammatory mechanisms — including reductions in C-reactive protein and other inflammatory markers — may partly explain benefits observed in non-alcoholic fatty liver disease (NAFLD), where semaglutide has shown reductions in hepatic steatosis and liver enzyme levels. The ongoing FOCUS trial is examining its impact on microvascular complications.

Perhaps most intriguing are the emerging neurological and psychiatric applications. Observational and early clinical data suggest semaglutide may reduce the risk of Alzheimer's disease, potentially through anti-inflammatory and neuroprotective pathways mediated by central GLP-1 receptors. Similarly, reduced alcohol cravings observed in clinical settings have prompted investigation into semaglutide for alcohol use disorder. Additional conditions under active study include polycystic ovary syndrome (PCOS), where weight loss improves hormonal profiles, and obstructive sleep apnea (OSA), where the SELECT trial showed a 20% reduction in apnea-hypopnea index independent of weight loss.

Gastrointestinal adverse effects — nausea, vomiting, diarrhea — remain the most frequent side effects and are the primary reason for discontinuation, though they are typically transient and dose-dependent. The availability of both weekly subcutaneous injections (Ozempic/Wegovy) and a daily oral tablet (Rybelsus) broadens patient access and adherence options. The authors acknowledge that many emerging indications still require large, dedicated randomized controlled trials, and that populations such as those with non-diabetic cardiovascular disease or advanced hepatic fibrosis remain understudied.